A Brief Review of in Vitro Models of Diabetic Neuropathy

i. International Diabetes Federation. Diabetes Atlas 2019. 9th ed. Brussels: IDF;2019.

2. Pirart J. Diabetes mellitus and its degenerative complications: a prospective written report of 4,400 patients observed between 1947 and 1973. Diabete Metab. 1977; 3:97–107.

3. Velayudhan L, Poppe Yard, Archer Northward, Proitsi P, Dark-brown RG, Lovestone S. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry. 2010; 196:36–40.

four. Pop-Busui R, Martin C. Neuropathy in the DCCT/EDIC: what was washed so and what we would exercise better now. Int Rev Neurobiol. 2016; 127:nine–25.

5. Alam U, Sloan Chiliad, Tesfaye S. Treating pain in diabetic neuropathy: electric current and developmental drugs. Drugs. 2020; 80:363–84.

6. Rodriguez-Gutierrez R, Montori VM. Glycemic command for patients with blazon 2 diabetes mellitus: our evolving faith in the face up of evidence. Circ Cardiovasc Qual Outcomes. 2016; 9:504–12.

7. Fernyhough P, Calcutt NA. An introduction to the history and controversies of the pathogenesis of diabetic neuropathy. Int Rev Neurobiol. 2016; 127:115–20.

8. Calcutt NA, Fernyhough P. An introduction to the history and controversies of animate being models of diabetic neuropathy. Int Rev Neurobiol. 2016; 127:45–52.

9. Yagihashi S. Glucotoxic mechanisms and related therapeutic approaches. Int Rev Neurobiol. 2016; 127:121–49.

10. Zochodne DW. Sensory neurodegeneration in diabetes: across glucotoxicity. Int Rev Neurobiol. 2016; 127:151–fourscore.

eleven. Bril V. The perfect clinical trial. Int Rev Neurobiol. 2016; 127:27–41.

12. Vinik AI, Casellini C, Nevoret ML. Alternative quantitative tools in the assessment of diabetic peripheral and autonomic neuropathy. Int Rev Neurobiol. 2016; 127:235–85.

13. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement past the American Diabetes Clan. Diabetes Care. 2017; 40:136–54.

14. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011; 27:620–viii.

fifteen. Zilliox LA, Ruby SK, Singh S, Zhan 1000, Russell JW. Clinical neuropathy scales in neuropathy associated with dumb glucose tolerance. J Diabetes Complications. 2015; 29:372–7.

16. Kalichman MW, Chalk CH, Mizisin AP. Nomenclature of teased nerve fibers for multicenter clinical trials. J Peripher Nerv Syst. 1999; four:233–44.

17. Lauria 1000, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the utilize of skin biopsy in the diagnosis of minor fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nervus Society. Eur J Neurol. 2010; 17:903–12.

18. Petropoulos IN, Ponirakis Chiliad, Khan A, Almuhannadi H, Gad H, Malik RA. Diagnosing diabetic neuropathy: something old, something new. Diabetes Metab J. 2018; 42:255–69.

19. Malik RA. Wherefore art g, o handling for diabetic neuropathy? Int Rev Neurobiol. 2016; 127:287–317.

20. Kennedy WR, Wendelschafer-Crabb Thou, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology. 1996; 47:1042–8.

21. Malik RA, Tesfaye South, Newrick PG, Walker D, Rajbhandari SM, Siddique I, et al. Sural nerve pathology in diabetic patients with minimal only progressive neuropathy. Diabetologia. 2005; 48:578–85.

22. Quattrini C, Tavakoli G, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et al. Surrogate markers of minor fiber damage in human diabetic neuropathy. Diabetes. 2007; 56:2148–54.

23. Tavakoli M, Quattrini C, Abbott C, Kallinikos P, Marshall A, Finnigan J, et al. Corneal confocal microscopy: a novel noninvasive examination to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care. 2010; 33:1792–vii.

24. Tavee J. Nervus conduction studies: bones concepts. Handb Clin Neurol. 2019; 160:217–24.

25. Perkins B, Bril V. Electrophysiologic testing in diabetic neuropathy. Handb Clin Neurol. 2014; 126:235–48.

26. Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ. Tin can motor nervus conduction velocity predict foot issues in diabetic subjects over a 6-year outcome period? Diabetes Care. 2002; 25:2010–5.

27. Gibbons CH, Freeman R, Tecilazich F, Dinh T, Lyons TE, Gnardellis C, et al. The evolving natural history of neurophysiologic role in patients with well-controlled diabetes. J Peripher Nerv Syst. 2013; 18:153–61.

28. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in blazon two diabetes: the Fremantle Diabetes Written report. Diabetologia. 2008; 51:562–half dozen.

29. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, et al. Outcome of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet. 1998; Dec. 352:1978–81.

thirty. Polydefkis M, Arezzo J, Nash Chiliad, Bril V, Shaibani A, Gordon RJ, et al. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy. J Peripher Nerv Syst. 2015; 20:363–71.

31. Javed S, Petropoulos IN, Tavakoli G, Malik RA. Clinical and diagnostic features of small fiber damage in diabetic polyneuropathy. Handb Clin Neurol. 2014; 126:275–90.

32. Lee-Kubli C, Marshall AG, Malik RA, Calcutt NA. The H-reflex as a biomarker for spinal disinhibition in painful diabetic neuropathy. Curr Diab Rep. 2018; xviii:1.

33. Ishikawa K, Ott K, Porter RW, Stuart D. Low frequency depression of the H wave in normal and spinal human. Exp Neurol. 1966; 15:140–56.

34. Kakinohana O, Hefferan MP, Nakamura S, Kakinohana M, Galik J, Tomori Z, et al. Development of GABA-sensitive spasticity and rigidity in rats after transient spinal cord ischemia: a qualitative and quantitative electrophysiological and histopathological study. Neuroscience. 2006; 141:1569–83.

35. Jolivalt CG, Lee CA, Ramos KM, Calcutt NA. Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. Pain. 2008; 140:48–57.

36. Lee-Kubli CA, Calcutt NA. Altered rate-dependent depression of the spinal H-reflex equally an indicator of spinal disinhibition in models of neuropathic pain. Pain. 2014; 155:250–lx.

37. Marshall AG, Lee-Kubli C, Azmi S, Zhang G, Ferdousi Grand, Mixcoatl-Zecuatl T, et al. Spinal disinhibition in experimental and clinical painful diabetic neuropathy. Diabetes. 2017; 66:1380–90.

38. Serra J. Microneurography: towards a biomarker of spontaneous pain. Pain. 2012; 153:1989–90.

39. Kleggetveit IP, Namer B, Schmidt R, Helas T, Ruckel Yard, Orstavik G, et al. High spontaneous activity of C-nociceptors in painful polyneuropathy. Hurting. 2012; 153:2040–7.

40. Ochoa JL, Campero M, Serra J, Bostock H. Hyperexcitable polymodal and insensitive nociceptors in painful human neuropathy. Muscle Nerve. 2005; 32:459–72.

41. Serra J. Microneurography: an opportunity for translational drug development in neuropathic pain. Neurosci Lett. 2010; 470:155–seven.

42. Serra J, Duan WR, Locke C, Sola R, Liu Westward, Nothaft W. Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Hurting. 2015; 156:2175–83.

43. Dyck PJ, Dyck PJ, Larson TS, O'Brien PC, Velosa JA. Patterns of quantitative awareness testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy: a study of three cohorts. Nervus growth factor written report grouping. Diabetes Care. 2000; 23:510–seven.

44. Backonja MM, Attal N, Baron R, Bouhassira D, Drangholt M, Dyck PJ, et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain. 2013; 154:1807–xix.

45. Bird SJ, Brown MJ, Spino C, Watling S, Foyt HL. Value of repeated measures of nerve conduction and quantitative sensory testing in a diabetic neuropathy trial. Musculus Nervus. 2006; 34:214–24.

46. Gelber DA, Pfeifer MA, Broadstone VL, Munster EW, Peterson M, Arezzo JC, et al. Components of variance for vibratory and thermal threshold testing in normal and diabetic subjects. J Diabetes Complications. 1995; 9:170–half-dozen.

47. Shy ME, Frohman EM, And so YT, Arezzo JC, Cornblath DR, Giuliani MJ, et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American University of Neurology. Neurology. 2003; 60:898–904.

48. Devigili 1000, Tugnoli 5, Penza P, Camozzi F, Lombardi R, Melli G, et al. The diagnostic criteria for modest fibre neuropathy: from symptoms to neuropathology. Encephalon. 2008; 131(Pt 7):1912–25.

49. Wahren J, Foyt H, Daniels M, Arezzo JC. Long-acting C-peptide and neuropathy in blazon i diabetes: a 12-month clinical trial. Diabetes Intendance. 2016; 39:596–602.

50. Melzack R. The brusk-form McGill Pain Questionnaire. Hurting. 1987; 30:191–7.

51. Zelman DC, Gore M, Dukes E, Tai KS, Brandenburg N. Validation of a modified version of the Brief Pain Inventory for painful diabetic peripheral neuropathy. J Vasc Nurs. 2005; 23:97–104.

52. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Hurting Symptom Inventory. Pain. 2004; 108:248–57.

53. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A applied ii-pace quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994; 17:1281–ix.

54. Abraham A, Barnett C, Katzberg Hard disk drive, Lovblom LE, Perkins BA, Bril V. Toronto Clinical Neuropathy Score is valid for a broad spectrum of polyneuropathies. Eur J Neurol. 2018; 25:484–90.

55. Powell HC, Rosoff J, Myers RR. Microangiopathy in human diabetic neuropathy. Acta Neuropathol. 1985; 68:295–305.

56. Kalichman MW, Powell HC, Mizisin AP. Reactive, degenerative, and proliferative Schwann prison cell responses in experimental galactose and human being diabetic neuropathy. Acta Neuropathol. 1998; 95:47–56.

57. Llewelyn JG, Gilbey SG, Thomas PK, Rex RH, Muddle JR, Watkins PJ. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study. Brain. 1991; 114(Pt 2):867–92.

58. Mizisin AP, Nelson RW, Sturges BK, Vernau KM, Lecouteur RA, Williams DC, et al. Comparable myelinated nerve pathology in feline and human diabetes mellitus. Acta Neuropathol. 2007; 113:431–42.

59. Sima AA, Bril V, Nathaniel V, McEwen TA, Brown MB, Lattimer SA, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. Due north Engl J Med. 1988; 319:548–55.

sixty. Sima AA, Greene DA, Brownish MB, Hohman TC, Hicks D, Graepel GJ, et al. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Grouping. J Diabetes Complications. 1993; vii:157–69.

61. Breiner A, Lovblom LE, Perkins BA, Bril V. Does the prevailing hypothesis that small-scale-fiber dysfunction precedes big-fiber dysfunction apply to type 1 diabetic patients? Diabetes Care. 2014; 37:1418–24.

62. Lauria G, Bakkers M, Schmitz C, Lombardi R, Penza P, Devigili One thousand, et al. Intraepidermal nerve cobweb density at the distal leg: a worldwide normative reference written report. J Peripher Nerv Syst. 2010; 15:202–7.

63. Pittenger GL, Mehrabyan A, Simmons Thousand, Amandarice , Dublin C, Barlow P, et al. Pocket-sized cobweb neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord. 2005; 3:113–21.

64. Azmi Due south, Jeziorska M, Ferdousi Chiliad, Petropoulos IN, Ponirakis G, Marshall A, et al. Early nerve fibre regeneration in individuals with blazon i diabetes later on simultaneous pancreas and kidney transplantation. Diabetologia. 2019; 62:1478–87.

65. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nervus Social club guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2010; xv:79–92.

66. Doss AL, Smith PG. Nerve-Langerhans jail cell interactions in diabetes and aging. Histol Histopathol. 2012; 27:1589–98.

67. Collongues N, Samama B, Schmidt-Mutter C, Chamard-Witkowski Fifty, Debouverie M, Chanson JB, et al. Quantitative and qualitative normative dataset for intraepidermal nervus fibers using skin biopsy. PLoS 1. 2018; 13:e0191614.

68. Cheng HT, Dauch JR, Porzio MT, Yanik BM, Hsieh W, Smith AG, et al. Increased axonal regeneration and swellings in intraepidermal nerve fibers characterize painful phenotypes of diabetic neuropathy. J Pain. 2013; 14:941–7.

69. Cheung A, Podgorny P, Martinez JA, Chan C, Toth C. Epidermal axonal swellings in painful and painless diabetic peripheral neuropathy. Muscle Nervus. 2015; 51:505–xiii.

seventy. Lauria G, Morbin One thousand, Lombardi R, Borgna M, Mazzoleni Chiliad, Sghirlanzoni A, et al. Axonal swellings predict the degeneration of epidermal nerve fibers in painful neuropathies. Neurology. 2003; 61:631–6.

71. Khoshnoodi Thousand, Truelove S, Polydefkis M. Effect of diabetes type on long-term issue of epidermal axon regeneration. Ann Clin Transl Neurol. 2019; 6:2088–96.

72. Wang N, Gibbons CH. Skin biopsies in the assessment of the autonomic nervous organisation. Handb Clin Neurol. 2013; 117:371–viii.

73. Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology. 2001; 57:1701–four.

74. Kluding PM, Pasnoor M, Singh R, Jernigan Southward, Farmer K, Rucker J, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012; 26:424–9.

75. Singleton JR, Marcus RL, Jackson JE, Lessard MK, Graham TE, Smith AG. Practice increases cutaneous nerve density in diabetic patients without neuropathy. Ann Clin Transl Neurol. 2014; one:844–ix.

76. Smith AG, Russell J, Feldman EL, Goldstein J, Peltier A, Smith S, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006; 29:1294–nine.

77. Perkins BA, Lovblom LE, Bril V, Scarr D, Ostrovski I, Orszag A, et al. Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia. 2018; 61:1856–61.

78. Dabbah MA, Graham J, Petropoulos IN, Tavakoli 1000, Malik RA. Automatic assay of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging. Med Image Anal. 2011; 15:738–47.

79. Williams BM, Borroni D, Liu R, Zhao Y, Zhang J, Lim J, et al. An artificial intelligence-based deep learning algorithm for the diagnosis of diabetic neuropathy using corneal confocal microscopy: a development and validation report. Diabetologia. 2020; 63:419–30.

80. Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron Northward, et al. Corneal confocal microscopy: a non-invasive surrogate of nervus fibre damage and repair in diabetic patients. Diabetologia. 2003; 46:683–8.

81. Petropoulos IN, Alam U, Fadavi H, Marshall A, Asghar O, Dabbah MA, et al. Rapid automatic diagnosis of diabetic peripheral neuropathy with in vivo corneal confocal microscopy. Invest Ophthalmol Vis Sci. 2014; 55:2071–8.

82. Petropoulos IN, Manzoor T, Morgan P, Fadavi H, Asghar O, Alam U, et al. Repeatability of in vivo corneal confocal microscopy to quantify corneal nerve morphology. Cornea. 2013; 32:e83–ix.

83. Chen X, Graham J, Dabbah MA, Petropoulos IN, Ponirakis Thou, Asghar O, et al. Pocket-sized nerve cobweb quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density. Diabetes Intendance. 2015; 38:1138–44.

84. Dehghani C, Pritchard N, Edwards K, Russell AW, Malik RA, Efron N. Run a risk factors associated with corneal nervus alteration in blazon 1 diabetes in the absenteeism of neuropathy: a longitudinal in vivo corneal confocal microscopy study. Cornea. 2016; 35:847–52.

85. Jia X, Wang X, Wang Ten, Pan Q, Xian T, Yu X, et al. In vivo corneal confocal microscopy detects improvement of corneal nervus parameters following glycemic control in patients with type two diabetes. J Diabetes Res. 2018; 2018:8516276.

86. Jolivalt CG, Frizzi KE, Guernsey Fifty, Marquez A, Ochoa J, Rodriguez K, et al. Peripheral neuropathy in mouse models of diabetes. Curr Protoc Mouse Biol. 2016; 6:223–55.

87. Gardiner NJ, Freeman OJ. Tin can diabetic neuropathy be modeled in vitro? Int Rev Neurobiol. 2016; 127:53–87.

88. Goncalves NP, Vaegter CB, Andersen H, Ostergaard L, Calcutt NA, Jensen TS. Schwann jail cell interactions with axons and microvessels in diabetic neuropathy. Nat Rev Neurol. 2017; 13:135–47.

89. Hadimani MB, Purohit MK, Vanampally C, Van der Ploeg R, Arballo V, Morrow D, et al. Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy. J Med Chem. 2013; 56:5071–eight.

ninety. Habash T, Saleh A, Roy Chowdhury SK, Smith DR, Fernyhough P. The proinflammatory cytokine, interleukin-17A, augments mitochondrial function and neurite outgrowth of cultured adult sensory neurons derived from normal and diabetic rats. Exp Neurol. 2015; 273:177–89.

91. Takaku S, Yako H, Niimi N, Akamine T, Kawanami D, Utsunomiya K, et al. Institution of a myelinating co-civilisation system with a motor neuron-like cell line NSC-34 and an adult rat Schwann cell line IFRS1. Histochem Jail cell Biol. 2018; 149:537–43.

92. Urban MJ, Li C, Yu C, Lu Y, Krise JM, McIntosh MP, et al. Inhibiting oestrus-shock poly peptide 90 reverses sensory hypoalgesia in diabetic mice. ASN Neuro. 2010; ii:e00040.

93. Biessels GJ, Bril Five, Calcutt NA, Cameron NE, Cotter MA, Dobrowsky R, et al. Phenotyping animal models of diabetic neuropathy: a consensus statement of the diabetic neuropathy study grouping of the EASD (Neurodiab). J Peripher Nerv Syst. 2014; nineteen:77–87.

94. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nervus fiber quantification in the assessment of diabetic neuropathy. Acta Histochem. 2008; 110:351–62.

95. Chen DK, Frizzi KE, Guernsey LS, Ladt G, Mizisin AP, Calcutt NA. Repeated monitoring of corneal nerves by confocal microscopy as an alphabetize of peripheral neuropathy in type-1 diabetic rodents and the effects of topical insulin. J Peripher Nerv Syst. 2013; 18:306–fifteen.

96. Jakobsen J. Axonal dwindling in early on experimental diabetes. II. A study of isolated nervus fibres. Diabetologia. 1976; 12:547–53.

97. Jakobsen J. Axonal dwindling in early experimental diabetes. I. A written report of cross sectioned nerves. Diabetologia. 1976; 12:539–46.

98. Jakobsen J, Sidenius P, Gundersen HJ, Osterby R. Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes. 1987; 36:597–601.

99. Sidenius P, Jakobsen J. Reduced perikaryal book of lower motor and main sensory neurons in early on experimental diabetes. Diabetes. 1980; 29:182–vi.

100. Thomas PK, Fraher JP, O'Leary D, Moran MA, Cole M, Rex RH. Relative growth and maturation of axon size and myelin thickness in the tibial nerve of the rat. 2. Effect of streptozotocin-induced diabetes. Acta Neuropathol. 1990; 79:375–86.

101. Anderson NJ, Rex MR, Delbruck Fifty, Jolivalt CG. Office of insulin signaling damage, adiponectin and dyslipidemia in peripheral and central neuropathy in mice. Dis Model Mech. 2014; 7:625–33.

102. Sima AA. Encephalopathies: the emerging diabetic complications. Acta Diabetol. 2010; 47:279–93.

103. Biessels GJ, Nobili F, Teunissen CE, Simo R, Scheltens P. Understanding multifactorial encephalon changes in type 2 diabetes: a biomarker perspective. Lancet Neurol. 2020; nineteen:699–710.

104. Kennedy JM, Zochodne DW. Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? Diabetes. 2005; 54:830–seven.

105. Mattingly GE, Fischer VW. Peripheral neuropathy following prolonged exposure to streptozotocin-induced diabetes in rats: a teased nerve fiber study. Acta Neuropathol. 1983; 59:133–viii.

106. Powell HC, Myers RR. Axonopathy and microangiopathy in chronic alloxan diabetes. Acta Neuropathol. 1984; 65:128–37.

107. Robertson DM, Sima AA. Diabetic neuropathy in the mutant mouse [C57BL/ks(db/db)]: a morphometric written report. Diabetes. 1980; 29:lx–seven.

108. Wada R, Koyama M, Mizukami H, Odaka H, Ikeda H, Yagihashi Due south. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type two diabetes. Diabetes Metab Res Rev. 1999; 15:332–seven.

109. Yagihashi S, Nishihira Thou, Baba M. Morphometrical assay of the peripheral nerve lesions in experimental diabetes rats. Tohoku J Exp Med. 1979; 129:139–49.

110. Gregory JA, Jolivalt CG, Goor J, Mizisin AP, Calcutt NA. Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathol. 2012; 124:561–73.

111. Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension equally a risk factor for diabetic neuropathy: a prospective written report. Diabetes. 1997; 46:665–70.

112. Romanovsky D, Hastings SL, Stimers JR, Dobretsov M. Relevance of hyperglycemia to early mechanical hyperalgesia in streptozotocin-induced diabetes. J Peripher Nerv Syst. 2004; 9:62–9.

113. Romanovsky D, Cruz NF, Dienel GA, Dobretsov M. Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis. 2006; 24:384–94.

114. Romanovsky D, Dobretsov M. Pressure level-induced hurting: early sign of diabetes-associated harm of insulin product in rats. Neurosci Lett. 2010; 483:110–iii.

115. Pabbidi RM, Cao DS, Parihar A, Pauza ME, Premkumar LS. Direct role of streptozotocin in inducing thermal hyperalgesia by enhanced expression of transient receptor potential vanilloid ane in sensory neurons. Mol Pharmacol. 2008; 73:995–1004.

116. Andersson DA, Filipovic MR, Gentry C, Eberhardt M, Vastani N, Leffler A, et al. Streptozotocin stimulates the ion aqueduct TRPA1 straight: involvement of peroxynitrite. J Biol Chem. 2015; 290:15185–96.

117. Karunanayake EH, Hearse DJ, Mellows G. The synthesis of [14C] streptozotocin and its distribution and excretion in the rat. Biochem J. 1974; 142:673–83.

118. Davidson East, Coppey L, Lu B, Arballo V, Calcutt NA, Gerard C, et al. The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine experimental diabetic neuropathy. Exp Diabetes Res. 2009; 2009:431980.

119. Yorek MA. Alternatives to the streptozotocin-diabetic rodent. Int Rev Neurobiol. 2016; 127:89–112.

120. Walker D, Carrington A, Cannan SA, Sawicki D, Sredy J, Boulton AJ, et al. Structural abnormalities exercise non explicate the early functional abnormalities in the peripheral nerves of the streptozotocin diabetic rat. J Anat. 1999; 195(Pt 3):419–27.

121. Tomlinson DR, Moriarty RJ, Mayer JH. Prevention and reversal of defective axonal send and motor nerve conduction velocity in rats with experimental diabetes by handling with the aldose reductase inhibitor sorbinil. Diabetes. 1984; 33:470–six.

122. Oates PJ. Aldose reductase, withal a compelling target for diabetic neuropathy. Curr Drug Targets. 2008; ix:14–36.

123. Coderre TJ, Laferriere A. The emergence of animal models of chronic pain and logistical and methodological bug apropos their use. J Neural Transm (Vienna). 2020; 127:393–406.

124. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001; 53:597–652.

125. Lee-Kubli CA, Calcutt NA. Painful neuropathy: mechanisms. Handb Clin Neurol. 2014; 126:533–57.

126. Calcutt NA, Malmberg AB, Yamamoto T, Yaksh TL. Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats. Pain. 1994; 58:413–20.

127. Ohsawa One thousand, Kashiwazaki T, Kamei J. Modulation of the formalin-induced nociceptive response by diabetes: possible interest of protein kinase C. Brain Res. 1998; 803:198–203.

128. Calcutt NA. Modeling diabetic sensory neuropathy in rats. Methods Mol Med. 2004; 99:55–65.

129. Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain. 2016; 157:1132–45.

130. Jourdan D, Ardid D, Eschalier A. Analysis of ultrasonic vocalization does not allow chronic pain to be evaluated in rats. Hurting. 2002; 95:165–73.

131. Chen 10, Levine JD. Hyper-responsivity in a subset of C-fiber nociceptors in a model of painful diabetic neuropathy in the rat. Neuroscience. 2001; 102:185–92.

132. Khan GM, Chen SR, Pan HL. Role of primary afferent nerves in allodynia acquired by diabetic neuropathy in rats. Neuroscience. 2002; 114:291–ix.

133. Schuelert N, Gorodetskaya N, Just Southward, Doods H, Corradini Fifty. Electrophysiological characterization of spinal neurons in unlike models of diabetes type ane- and type 2-induced neuropathy in rats. Neuroscience. 2015; 291:146–54.

134. Chen SR, Pan HL. Hypersensitivity of spinothalamic tract neurons associated with diabetic neuropathic hurting in rats. J Neurophysiol. 2002; 87:2726–33.

135. Tan AM, Samad OA, Fischer TZ, Zhao P, Persson AK, Waxman SG. Maladaptive dendritic spine remodeling contributes to diabetic neuropathic pain. J Neurosci. 2012; 32:6795–807.

136. Pertovaara A, Wei H, Kalmari J, Ruotsalainen M. Pain behavior and response properties of spinal dorsal horn neurons following experimental diabetic neuropathy in the rat: modulation by nitecapone, a COMT inhibitor with antioxidant properties. Exp Neurol. 2001; 167:425–34.

137. Calcutt NA, Stiller C, Gustafsson H, Malmberg AB. Elevated substance-P-like immunoreactivity levels in spinal dialysates during the formalin test in normal and diabetic rats. Encephalon Res. 2000; 856:20–7.

138. Malmberg AB, O'Connor WT, Glennon JC, Cesena R, Calcutt NA. Impaired formalin-evoked changes of spinal amino acrid levels in diabetic rats. Brain Res. 2006; 1115:48–53.

139. Wei H, Viisanen H, Amorim D, Koivisto A, Pertovaara A. Dissociated modulation of conditioned place-preference and mechanical hypersensitivity by a TRPA1 aqueduct antagonist in peripheral neuropathy. Pharmacol Biochem Behav. 2013; 104:90–6.

140. Wagner Grand, Lee KS, Yang J, Hammock BD. Epoxy fatty acids mediate analgesia in murine diabetic neuropathy. Eur J Pain. 2017; 21:456–65.

141. Wagner Thousand, Yang J, Inceoglu B, Hammock BD. Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. J Pain. 2014; 15:907–14.

142. Agarwal N, Helmstadter J, Rojas DR, Bali KK, Gangadharan V, Kuner R. Evoked hypoalgesia is accompanied by tonic pain and immune cell infiltration in the dorsal root ganglia at late stages of diabetic neuropathy in mice. Mol Pain. 2018; 14:17448–06918817975.

143. Davidson EP, Coppey LJ, Holmes A, Yorek MA. Changes in corneal innervation and sensitivity and acetylcholine-mediated vascular relaxation of the posterior ciliary avenue in a type 2 diabetic rat. Invest Ophthalmol Vis Sci. 2012; 53:1182–seven.

144. Beiswenger KK, Calcutt NA, Mizisin AP. Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett. 2008; 442:267–72.

145. Calcutt NA, Chen P, Hua XY. Effects of diabetes on tissue content and evoked release of calcitonin gene-related peptide-similar immunoreactivity from rat sensory nerves. Neurosci Lett. 1998; 254:129–32.

146. Tomlinson DR, Fernyhough P, Diemel LT. Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci. 1996; 351:455–62.

147. Fernyhough P, Calcutt NA. New directions in diabetic neuropathy: evolution or extinction? Int Rev Neurobiol. 2016; 127:229–34.

148. Davidson EP, Coppey LJ, Shevalye H, Obrosov A, Kardon RH, Yorek MA. Dumb corneal awareness and nerve loss in a type ii rat model of chronic diabetes is reversible with combination therapy of menhaden oil, α-lipoic acid, and enalapril. Cornea. 2017; 36:725–31.

149. Calcutt NA, Smith DR, Frizzi 1000, Sabbir MG, Chowdhury SK, Mixcoatl-Zecuatl T, et al. Selective antagonism of muscarinic receptors is neuroprotective in peripheral neuropathy. J Clin Invest. 2017; 127:608–22.

websterpoempon1990.blogspot.com

Source: https://synapse.koreamed.org/articles/1146401